PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

SGD Pharma expands its offer in moulded and tubular pharmaceutical glass packaging at CPHI Milan 2026

SGD Pharma, a global market leader in pharmaceutical glass primary packaging solutions and industry trailblazer in sustainability and decarbonisation, will present its expanded portfolio of moulded and tubular glass products and services on booth 11F17 during CPHI Milan from 6th to 8th October 2026.

o   SGD Pharma will debut MySterinity Nasal, a new range of molded vials extending its established Sterinity approach*.
Designed for the growing high-value nasal drug delivery market driven by a rise in biologics with higher microbiological requirements, MySterinity Nasal offers pharmaceutical companies a flexible solution for enhanced quality and safety, as well as improved Total Cost of Ownership (TCO). The Type I U-Save nasal vials can be pre-washed, depyrogenated or sterilised, making them suitable for systemic therapies, CNS therapies and vaccines.

o   SGD Pharma also announces the launch of its Ready-to-Use (RTU) tubular vials for sensitive, high-value parenteral drugs.
Washed, depyrogenated and sterilised, the new RTU vials support pharmaceutical companies operating in aseptic fill-finish environments and seeking increased quality and safety. The tubular RTU vials will be produced at SGD Pharma’s Felino, Italy ISO 5 environment manufacturing site following its acquisition of Alphial. They will offer speed of delivery, improved TCO and the convenience of a single supplier for their complete range of RTU Type I vials.

o   SGD Pharma is also launching MySealian, a new GMP-compliant subcontracting service for customers and partners’ vials
This new service enables any glass manufacturer, pharmaceutical company or OEM to access SGD Pharma’s best-in-class Sealian treatment for their existing ranges of molded glass primary packaging products, with no capital investment. The Sealian internal glass vial treatment preserves the integrity of sensitive therapeutic products by creating a protective barrier coating. Its enhanced hydrophobic properties prevent high viscosity infusions from sticking to the internal surface of the vial, enabling clear product visibility, easy inspection and minimal product waste.

o   Sealian will now also be available as a treatment option for SDG Pharma’s new tubular vial solutions.

Olivier Rousseau, CEO of SGD Pharma comments: “One year after the acquisition of Alphial, SGD Pharma is well positioned to address the evolving challenges of the pharmaceutical industry, offering innovative products and solutions across both molded and tubular glass primary packaging. We are particularly proud that these innovations are developed within a comprehensive ESG framework, ensuring that sustainability considerations are embedded from the very outset of every project. “

Visit booth 11F17 at CPHI to explore SGD Pharma’s portfolio and meet the team driving the next generation of glass packaging innovations.

Visit the new website here: http://www.sgd-pharma.com

*SGD Pharma is partnered with SG EZ-fill® to offer washed, depyrogenated and sterilised Type I moulded glass vials developed to meet the rigorous requirements of the pharmaceutical industry, speed up time to market and reduce total cost of ownership because of increased quality and flexibility.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC